Filed with ASX · · 4 pages · English
The trial has shown one Complete Response in Mantle Cell Lymphoma and one Partial Response in Chronic Lymphocytic Leukemia among evaluated patients. The study aims to enhance antitumor activity in patients who have progressed on prior BTK inhibitor therapy. Overall, azer-cel has demonstrated a significant Overall Response Rate across diverse patient populations in the trial.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM [email protected] ASX Announcement Imugene Reports one Complete Response and one Partial Response in BTKi Combination Cohort of azer-cel Phase 1b Trial •Two further responses achieved at Day 28: one Complete Response (CR) in MantleCell...
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene